Keyword: Jazz Pharmaceuticals
While biopharma CEOs often catch the limelight for their multimillion-dollar paychecks, it is every diligent worker that forms a company—and some of them also get paid handsomely. Here, we rank the top 10 most generous biopharma companies by median employee pay in 2018.
Harmony Biosciences is only two years old and has never launched a drug, but Thursday, the company scored its first FDA nod.
Jazz officially launches its new sleepiness drug Sunosi with a stepped-up sales force and branded marketing for doctors and consumers alike.
Jazz Pharma's next drug launch is set for early July after a DEA scheduling for sleepiness drug Sunosi.
Jazz, Lundbeck and Alexion inked settlements over allegations their contributions to patient charities were designed to boost sales.
Jazz's Sunosi scored FDA approval to help narcolepsy and sleep apnea patients stay awake, but can't launch until it clears a final hurdle at DEA.
Jazz has some new selling points for its leukemia drug Vyxeos, so why did third-quarter sales fall short? Because it’s facing new barriers, too.
With a new drug up for FDA approval, Jazz is gets a jump on the launch by boosting awareness of excessive sleepiness that can come with sleep apnea.
In a busy week at the European Commission, Novartis’ Kymriah, Gilead’s Yescarta, Jazz's Vyxeos, Alnylam's Onpattro and others got approvals.